Journal Watch · Journal of Immunology · 2026

Viral-specific induction of cellular and soluble urokinase plasminogen activator receptor (suPAR) expression.

Elevated suPAR liberation was observed after murine CoV infection but not IAV infection-both of which led to increased MO/Mφ mRNA and cell-bound uPA and uPAR, and increased secreted uPA activity. uPA knockdown in MO/Mφs abrogated suPAR liberation and blunted tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6 induction post-CoV, suggesting that targeting co-regulators of uPAR and uPA may be beneficial in attenuating coronavirus-driven inflammatory cytokine responses, and treating diseases characterized by suPAR release from Mφs.

Sharma SB, Kumar K, Parchment N et al.Journal of Immunology3 min readPharma relevance 65/100

DOI: 10.1093/jimmun/vkaf365PMID: 41764719Study type: preclinical (animal / model) study

TL;DR

Elevated suPAR liberation was observed after murine CoV infection but not IAV infection-both of which led to increased MO/Mφ mRNA and cell-bound uPA and uPAR, and increased secreted uPA activity. uPA knockdown in MO/Mφs abrogated suPAR liberation and blunted tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6 induction post-CoV, suggesting that targeting co-regulators of uPAR and uPA may be beneficial in attenuating coronavirus-driven inflammatory cytokine responses, and treating diseases characterized by suPAR release from Mφs.

Key findings

  • Elevated suPAR liberation was observed after murine CoV infection but not IAV infection-both of which led to increased MO/Mφ mRNA and cell-bound uPA and uPAR, and increased secreted uPA activity. uPA knockdown in MO/Mφs abrogated suPAR liberation and blunted tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6 induction post-CoV, suggesting that targeting co-regulators of uPAR and uPA may be beneficial in attenuating coronavirus-driven inflammatory cytokine responses, and treating diseases characterized by suPAR release from Mφs.

What they did

How suPAR liberation from MO/Mφs occurs after CoV infection, and whether suPAR induction is exclusive to coronavirus infection or occurs from other clinically significant coagulopathy-inducing pneumotropic viral infections such as influenza A (IAV), is unknown. We noted increased PLAUR transcripts in peripheral blood mononuclear cells (PBMCs) from SARS-CoV-2-positive and IAV-positive patients.

Full abstract (original)

Background: Urokinase (uPA) and urokinase plasminogen activator receptor (uPAR/PLAUR) mediate fibrinolysis and matrix remodeling. Liberation of monocyte/macrophage (MO/Mφ)-bound soluble uPAR (suPAR) occurs after infection with coronaviruses (CoVs) such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), correlating with systemic inflammatory stress and end-organ injury severity.

What they did: How suPAR liberation from MO/Mφs occurs after CoV infection, and whether suPAR induction is exclusive to coronavirus infection or occurs from other clinically significant coagulopathy-inducing pneumotropic viral infections such as influenza A (IAV), is unknown. We noted increased PLAUR transcripts in peripheral blood mononuclear cells (PBMCs) from SARS-CoV-2-positive and IAV-positive patients.

Results & conclusions: Elevated suPAR liberation was observed after murine CoV infection but not IAV infection-both of which led to increased MO/Mφ mRNA and cell-bound uPA and uPAR, and increased secreted uPA activity. uPA knockdown in MO/Mφs abrogated suPAR liberation and blunted tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6 induction post-CoV, suggesting that targeting co-regulators of uPAR and uPA may be beneficial in attenuating coronavirus-driven inflammatory cytokine responses, and treating diseases characterized by suPAR release from Mφs.

Abstract © the authors / Journal of Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1093/jimmun/vkaf365 · PubMed 41764719.

Why it matters for pharma & biotech

  • Directly relevant to teams in mRNA / delivery technology — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: mRNA / delivery technology

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Journal of Immunology study find?

Elevated suPAR liberation was observed after murine CoV infection but not IAV infection-both of which led to increased MO/Mφ mRNA and cell-bound uPA and uPAR, and increased secreted uPA activity. uPA knockdown in MO/Mφs abrogated suPAR liberation and blunted tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6 induction post-CoV, suggesting that targeting co-regulators of uPAR and uPA may be beneficial in attenuating coronavirus-driven inflammatory cytokine responses, and treating diseases characterized by suPAR release from Mφs.

What type of study is this?

It is a preclinical (animal / model) study, published in Journal of Immunology in 2026. How suPAR liberation from MO/Mφs occurs after CoV infection, and whether suPAR induction is exclusive to coronavirus infection or occurs from other clinically significant coagulopathy-inducing pneumotropic viral infections such as influenza A (IAV), is unknown.

Where can I read the original paper?

The original is at the publisher via DOI 10.1093/jimmun/vkaf365. PubMed ID: 41764719. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Sharma SB, Kumar K, Parchment N et al.. Viral-specific induction of cellular and soluble urokinase plasminogen activator receptor (suPAR) expression.. Journal of Immunology (2026). DOI: 10.1093/jimmun/vkaf365.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/viral-specific-induction-of-cellular-and-soluble-urokinase-plasminogen-a-kaf365/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides